This study analyzed data from 186 postmenopausal, cancer-free women not currently using hormone therapy from the Susan G. Komen Tissue Bank to evaluate associations of individual PFASs and their chemical mixture with percent mammographic density and dense breast area.
Abstract
Background
Perfluoroalkyl substances (PFASs) are possible carcinogens with widespread population exposure. Mammographic density (MD) is a biomarker of breast cancer risk that may offer important insights into potential mechanisms of breast carcinogenesis. Examining associations between PFAS exposure and MD may elucidate pathways by which PFASs could affect breast cancer risk. However, associations between PFAS exposure and MD remain poorly studied. We sought to evaluate associations of individual PFASs and their chemical mixture with percent mammographic density and dense breast area.
Methods
We analyzed data from 186 postmenopausal, cancer-free women not currently using hormone therapy from the Susan G. Komen Tissue Bank. Percent mammographic density (PMD) and dense breast area (DBA) were measured from digital mammography images taken near the time of blood sample donation. Serum PFAS concentrations were measured using online solid-phase extraction followed by high-pressure liquid chromatography with tandem mass spectrometry (HPLC-MS/MS). Associations were examined using multivariable linear regression and Quantile g-computation.
Results
Participants had a mean age of 58.7 years and mean body mass index of 29.6 kg/m², and most were White (72.6%). The vast majority of mammograms were performed within 2 years of blood sample donation (88%). No statistically significant associations were observed with individual PFASs and either PMD or DBA in analyses adjusted for confounding variables. Quantile G-computation analyses did not identify a statistically significant effect of the PFAS mixture on PMD or DBA. Similar results were observed in analyses stratified by body mass index or breastfeeding history.
Conclusions
Overall, our study did not identify strong and significant associations between a panel of major PFASs and MD.
It is suggested that higher plasma PFAS concentrations, particularly HFPO-DA, may be associated with more advanced TNM stage in colorectal cancer and warrant confirmation in larger prospective studies.
Ning Kang, Yang Zhao, Zhi Huang et al.· Frontiers in Toxicology· 1 citation
BACKGROUND
Polyendocrine metabolic ovarian syndrome (PMOS) is a systemic endocrine and metabolic disorder that has been increasingly linked to exposure to environmental endocrine-disrupting chemicals. Although perfluoroalkyl and polyfluoroalkyl substances (PFASs) have been implicated as potential contributors, the comb...
Guang-Yu Cheng, Fang-Ning Li, Hong-Yu Li et al.· Clinica chimica acta; intern...· 0 citations
BACKGROUND
Parabens are widely used preservatives in personal care products and have demonstrated endocrine-disrupting and photosensitizing properties. However, their potential role in human skin carcinogenesis remains unclear.
METHODS
We analyzed a nationally representative sample of 9756 adults (aged 20-80) using d...
Yu-Dan Wei, S. Holder, Jian-Min Zhu et al.· Cancer Epidemiology· 0 citations
The need to reassess the biosafety of novel PFAS alternatives is underscores the need to reassess the biosafety of novel PFAS alternatives and provides new insights into the environmental etiology of breast cancer.
Bei Sun, Zhan-Hua Gao, Xi-Yue Liu et al.· Frontiers in Public Health· 0 citations
Perfluoroheptanoic acid (PFHpA) was positively associated with liver cancer risk and no associations were observed for other PFAS, and continued use of short-chain PFAS in consumer products is warranted.
C. Watling, J. Petrick, Barry I. Graubard et al.· Journal of the National Canc...· 0 citations
ABSTRACT We examined the association between serum uric acid (UA) levels and cancer incidence through a conventional observational and two‐sample Mendelian randomization (MR) study in the same population (triangulation). We followed 13,695 individuals aged 35–69 years for cancer incidence (total, gastric, colorectal, l...
Takashi Matsunaga, K. Wakai, T. Tamura et al.· Cancer Science· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.